The NHE3 inhibitor tenapanor prevents intestinal obstructions in CFTR-deleted mice
Xinjie Tan, Archana Kini, Dorothee Römermann, Ursula Seidler
Department of Gastroenterology, Hannover Medical School, Hannover, Germany
Running title: Tenapanor prevents intestinal obstruction in CF mice
Author for correspondence:
Ursula Seidler, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Straße 1, D 30625 Germany, Tel.: +495115329427; Fax No. +49 5115328428, email: Seidler.Ursula@mh-hannover.de
Word count: 3848
Acknowledgements: We acknowledge the help of all members of the institute for animal research of the MHH. A part of the graphical abstract was adapted from “Administration Techniques for Mice - Part 3”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates.
Conflict of interests: The authors have no conflict of interest to declare.
Funding: Cystic Fibrosis Trust SRC 011 and the Deutsche Forschungsgemeinschaft grants Se460/19-1 and For5046 Se460/22-1.
Authorship contributions: X.T., A.K and U.S designed the study, X.T., A.K and D.R. performed experiments, X.T., A.K and U.S. wrote the manuscript.
Data availability: The original data are available from the authors upon reasonable request.
Bullet points:
What is already known :
NHE3 inhibitor tenapanor increases luminal fluidity and alkalinity inCftr -/- mice during singlepass intestinal perfusion studies.